Evidence map›Paper›PMID 40979420›Full record

ArticleJournal of surgical case reports2025

Isolated splenic metastasis presenting at diagnosis of HER2-positive

Maika Yoshioka, Masafumi Shimoda, Kaori Abe, Nanae Masunaga, Masami Tsukabe, Tetsuhiro Yoshinami, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Kenzo Shimazu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maika YoshiokaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Masafumi ShimodaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Kaori AbeDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Nanae MasunagaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Masami TsukabeDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Yoshiaki SotaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Tomohiro MiyakeDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Tomonori TaneiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.
Kenzo ShimazuDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Splenic metastasis is uncommon, and truly isolated splenic metastasis (ISM) from breast cancer is a clinical rarity. Contemporary autopsy series reports splenic involvement in <1% of breast cancer-related deaths, and fewer than 15 well-documented ISM cases have been published. We report a 71-year-old woman presenting with a right-breast mass, regional lymphadenopathy, and a solitary splenic lesion detected on staging computed tomography (CT) and positron emission tomography-CT. Biopsy confirmed hormone receptor-negative, HER2-positive invasive ductal carcinoma. Six cycles of docetaxel, trastuzumab, and pertuzumab led to a 59% reduction in the primary tumour and complete radiological resolution of the splenic lesion. The patient remains progression-free 22 months after initiating therapy, maintained on trastuzumab and pertuzumab. Although extremely rare, ISM can present as the initial manifestation of

Indexed as

breast cancerHER2isolated metastasisspleen

Identifiers

PMID40979420
PMCPMC12449763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.